Home β€Ί Stock analysis β€Ί ICCM

IceCure Medical (ICCM) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)

Updated Oct 16, 2026, 4:00 PM ET

What changed since yesterday

ICCM rises 1.9% to $1.06. Closed at $1.06, +1.92% vs the prior close of $1.04. Day range $1.03–$1.10, opened at $1.04.

Last close$1.06+1.92%
Day range1.03–1.10
Open1.04
Volume101.37K
52-week range0.96–26.10
Avg volume (20d)185.49K

ICCM daily analysis β€” what happened

A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.

Oct 16, 2026 β€” ICCM rises 1.9% to $1.06
Oct 15, 2026 β€” ICCM ends flat (+0.0%) to $1.04
Oct 14, 2026 β€” ICCM slides 5.5% to $1.04, a 52-week low
Oct 13, 2026 β€” ICCM rises 1.9% to $1.10
Oct 12, 2026 β€” ICCM dips 1.8% to $1.08, a 52-week low, 7 down days in a row
Oct 9, 2026 β€” ICCM dips 2.7% to $1.10, a 52-week low, 6 down days in a row
Oct 8, 2026 β€” ICCM dips 1.7% to $1.13, a 52-week low on 2.2x normal volume
Oct 7, 2026 β€” ICCM slides 9.4% to $1.15, a 52-week low on 2.5x normal volume
Oct 6, 2026 β€” ICCM slides 17.5% to $1.27, a 52-week low on 4.0x normal volume
Oct 5, 2026 β€” ICCM dips 1.9% to $1.54, a 52-week low
Oct 2, 2026 β€” ICCM slides 7.1% to $1.57, a 52-week low on 2.4x normal volume

ICCM latest news & SEC filings

Every SEC filing by or about ICCM in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.

Oct 13, 2026 Β· Form 6-K β€” Report from a foreign company (6-K)

Report from a foreign company (6-K) β€” news it published at home

Source: SEC EDGAR filing 0001213900-26-108763

Oct 5, 2026 Β· Form 6-K β€” Report from a foreign company (6-K)

Report from a foreign company (6-K) β€” news it published at home

Source: SEC EDGAR filing 0001213900-26-106825

Oct 5, 2026 Β· Form 6-K β€” Report from a foreign company (6-K)

Report from a foreign company (6-K) β€” news it published at home

Source: SEC EDGAR filing 0001213900-26-106619

Sep 28, 2026 Β· Form 6-K β€” Report from a foreign company (6-K)

Report from a foreign company (6-K) β€” news it published at home

Source: SEC EDGAR filing 0001213900-26-104035

Sep 10, 2026 Β· Form 6-K β€” Report from a foreign company (6-K)

Report from a foreign company (6-K) β€” news it published at home

Source: SEC EDGAR filing 0001213900-26-098595

Aug 24, 2026 Β· Form 6-K β€” Report from a foreign company (6-K)

Report from a foreign company (6-K) β€” news it published at home

Source: SEC EDGAR filing 0001213900-26-092807

Aug 18, 2026 Β· Form EFFECT β€” EFFECT filing

EFFECT filing

Source: SEC EDGAR filing 9999999995-26-002690

Aug 18, 2026 Β· Form EFFECT β€” EFFECT filing

EFFECT filing

Source: SEC EDGAR filing 9999999995-26-002689

Aug 17, 2026 Β· Form 4 β€” Insider trade

Insider trade report (Form 4) β€” a director, officer or 10%+ owner changed their holdings

Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).

Source: SEC EDGAR filing 0001213900-26-090515

Aug 17, 2026 Β· Form 3 β€” New insider holdings

Initial insider ownership statement (Form 3) β€” a new director, officer or 10% owner disclosed their holdings

Source: SEC EDGAR filing 0001213900-26-090511

Aug 17, 2026 Β· Form 4 β€” Insider trade

Insider trade report (Form 4) β€” a director, officer or 10%+ owner changed their holdings

Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).

Source: SEC EDGAR filing 0001213900-26-090510

Aug 17, 2026 Β· Form 4 β€” Insider trade

Insider trade report (Form 4) β€” a director, officer or 10%+ owner changed their holdings

Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).

Source: SEC EDGAR filing 0001213900-26-090509

Aug 17, 2026 Β· Form 4 β€” Insider trade

Insider trade report (Form 4) β€” a director, officer or 10%+ owner changed their holdings

Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).

Source: SEC EDGAR filing 0001213900-26-090508

Aug 17, 2026 Β· Form 4 β€” Insider trade

Insider trade report (Form 4) β€” a director, officer or 10%+ owner changed their holdings

Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).

Source: SEC EDGAR filing 0001213900-26-090507

Aug 14, 2026 Β· Form S-8 β€” Employee share plan registration

Registration of shares for employee stock plans (S-8)

Source: SEC EDGAR filing 0001213900-26-090288

Things to know before you trade ICCM

ICCM market data (last 20 sessions)

DateOpenHighLowCloseVolume
Oct 16, 20261.041.101.031.06101.37K
Oct 15, 20261.041.071.001.0493.60K
Oct 14, 20261.091.090.961.04150.60K
Oct 13, 20261.111.131.031.10261.90K
Oct 12, 20261.111.191.061.0878.50K
Oct 9, 20261.171.171.051.10124.70K
Oct 8, 20261.151.211.041.13326.80K
Oct 7, 20261.291.301.151.15354.80K
Oct 6, 20261.491.511.091.27533.10K
Oct 5, 20261.591.611.471.54159.20K
Oct 2, 20261.731.791.551.57307.40K
Oct 1, 20261.651.731.611.69157.10K
Sep 30, 20261.631.821.601.62320.60K
Sep 29, 20261.651.691.561.59191.40K
Sep 28, 20261.711.771.601.6386.90K
Sep 25, 20261.801.901.651.73115.00K
Sep 24, 20261.871.941.711.7390.90K
Sep 23, 20261.942.021.831.8783.90K
Sep 22, 20261.982.041.941.95101.10K
Sep 21, 20261.992.081.951.9570.90K

About IceCure Medical

IceCure Medical (ICCM) is listed on the Nasdaq and classified by the SEC under β€œSurgical & Medical Instruments & Apparatus”. Its business address is in CAESAREA. State of incorporation: Israel. Fiscal year ends December 31. SEC CIK 1584371.

ICCM board of directors & executives

From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).

Directors

NameRoleLatest filing
Vincent Chun Hung ChanDirectorAug 17, 2026
Yang HuangDirectorMar 25, 2026
Sharon LevitaDirectorMar 25, 2026
Yonatan MalcaDirectorMar 25, 2026
Ron MayronDirectorMar 25, 2026
David SaltonDirectorAug 17, 2026
Eyal ShamirChief Executive OfficerMar 25, 2026

Executive officers

NameTitleLatest filing
Merav Nir DotanVP, Human ResourcesAug 17, 2026
Shad GoodVP, Sales for North AmericaAug 17, 2026
Shay LevavChief Operating OfficerAug 17, 2026
Naum MuchnikVP, R&D & EngineeringMay 18, 2026
Meir PelegChief Financial OfficerAug 17, 2026
Eyal ShamirChief Executive OfficerMar 25, 2026
Tlalit Bussi Tel-TzureVP, BD & Global MarketingAug 17, 2026
Ronen TsimermanChief Financial OfficerMay 18, 2026

Recent insider buys & sales

DateInsiderTypeSharesPrice
No open-market insider buys or sales reported in the last 12 months.

ICCM financials (annual, from XBRL filings)

Fiscal year endRevenueNet incomeDiluted EPSOperating cash flow
No annual XBRL figures available (foreign filers often report on Form 20-F).

Latest balance sheet: total assets $β€”, total liabilities $β€”, cash $β€”.

ICCM earnings / results-day log

DateFilingClose that day
No 8-K earnings releases in recent filings.

Related stocks Β· Surgical & Medical Instruments & Apparatus

Boston Scientific (BSX)Stryker (SYK)3M (MMM)Dexcom (DXCM)Medline (MDLN)Becton Dickinson (BDX)MiniMed (MMED)Resmed (RMD)Insulet (PODD)West Pharmaceutical Services (WST)

Popular today

Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)

More on ICCM

Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.